(Company Registration No. 199206445M)

Metech International Limited

(Incorporated in the Republic of Singapore)

Condensed interim financial statements
For the three months and nine months ended 30 September 2026

*Metech International Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to inform the shareholders of the Company that pursuant to Rules 705(2)(e) and 705(2C) of the Singapore Exchange Securities Trading Limited's (the "**Exchange**") Listing Manual Section B: Rules of Catalist (the "**Catalist Rules**"), the Company is required to announce its quarterly financial statements in view of the material uncertainty relating to going concern disclosed in the Company's financial statements for the financial year ended 31 December 2025.*

*This announcement has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

(Company Registration No. 199206445M)

Table of contents

		Page
A.	Condensed interim consolidated statement of profit or loss and other comprehensive income	**1**
B.	Condensed interim statements of financial position	**3**
C.	Condensed interim statements of changes in equity	**4**
D.	Condensed interim consolidated statement of cash flows	**6**
E.	Notes to the condensed interim consolidated financial statements	**8**
F.	Other information required pursuant to Appendix 7C of the Catalist Rules	**27**

METech

(Company Registration No. 199206445M)

UNAUDITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ("Q3FY") AND NINE MONTHS ("9MFY") ENDED 30 SEPTEMBER 2026.

A. Condensed interim consolidated statement of profit or loss and other comprehensive income

		The Group			The Group		
		3-months period ended 30/09/2026 (Q3FY2026) Unaudited	3-months period ended 30/09/2025 (Q3FY2025) Unaudited	Inc/(Dec)	**9-months period ended 30/09/2026 (9MFY2026) Unaudited**	9-months period ended 30/09/2025 (9MFY2025) Unaudited	Inc/(Dec)
	Note	**S$'000**	**S$'000**	**%**	**S$'000**	**S$'000**	**%**
Revenue	4	**-**	-	n.m.	**3,210**	3,061	4.87
Cost of sales		**-**	-	n.m.	**(2,605)**	(2,723)	(4.33)
Gross profit		**-**	-	n.m.	**605**	338	78.99
Gross profit margin		**-**	-		**18.85%**	11.04%	
Other income:							
Others	6	**156**	6	n.m.	**522**	14	n.m.
Interest income		*****	*	n.m.	*****	*	n.m.
Expenses:							
Administrative expenses		**(1,211)**	(283)	327.92	**(1,832)**	(993)	84.49
Finance costs		**-**	(2)	n.m.	**-**	(7)	n.m.
Loss before income tax	7	**(1,055)**	(279)		**(705)**	(648)	
Income tax expense	8	**-**	-	n.m.	**-**	-	n.m.
Loss after income tax		**(1,055)**	(279)		**(705)**	(648)	
Discontinued operations							
Loss from discontinued operations		**(*)**	(16)	n.m.	**(*)**	(46)	n.m.
Total loss		**(1,055)**	(295)		**(705)**	(694)	
Other comprehensive (loss)/income, net of income tax:							
Foreign currency translation difference		**(4)**	4	n.m.	**12**	2	n.m.
Total comprehensive (loss)/income for the financial period		**(1,059)**	(291)		**(693)**	(692)	
Loss attributable to:							
Equity holders of the Company		**(1,055)**	(291)	259.11	**(705)**	(685)	1.46
Non-controlling interests		**(*)**	(4)	n.m.	**(*)**	(9)	n.m.
		(1,055)	(295)		**(705)**	(694)	
Total loss attributable to equity holders of the Company							
Loss from continuing operations		**(1,055)**	(291)	264.11	**(705)**	(685)	1.76
Loss from discontinued operations		**(*)**	(4)	n.m.	**(*)**	(9)	n.m.
		(1,055)	(295)		**(705)**	(694)	
Total comprehensive loss for the period attributable to:							
Equity holders of the Company		**(1,059)**	(287)		**(693)**	(683)	
Non-controlling interests		**(*)**	(4)		**(*)**	(9)	
		(1,059)	(291)		**(693)**	(692)	

	Note	The Group			The Group		
		3-months period ended 30/06/2026 (Q2FY2026) Unaudited	3-months period ended 30/06/2025 (Q2FY2025) Unaudited	Inc/(Dec)	**6-months period ended 30/06/2026 (HY2026) Unaudited**	6-months period ended 30/06/2025 (HY2025) Unaudited	Inc/(Dec)
		S$'000	**S$'000**	**%**	**S$'000**	**S$'000**	**%**
Basic and diluted profit/(loss) per share (cents per share) attributable to the equity holders of the Company							
Continuing operations		**(0.45)**	(0.16)		**(0.30)**	(0.37)	
Discontinued operations		**(*)**	(*)		**(*)**	(*)	
Total		**(0.45)**	(0.16)		**(0.30)**	(0.37)	

Notes:

(1) * denotes amounts less than S$1,000 or amounts less than 0.01 cents per share (as applicable)
(2) n.m. means not meaningful

The calculation of basic and diluted loss per ordinary share was based on a weighted average of 234,156,775 shares from 1 January 2026 to 30 September 2026 (1 January 2025 to 30 September 2025: 183,280,597).

B. Condensed interim statements of financial position

	Note	The Group		The Company	
		As at 30/09/2026 Unaudited	As at 31/12/2025 Audited	As at 30/09/2026 Unaudited	As at 31/12/2025 Audited
		S$'000	S$'000	S$'000	S$'000
ASSETS					
Non-current Assets					
Property, plant and equipment	11	135	44	2	1
Investments in subsidiaries	12	-	-	-	-
Total Non-current Assets		135	44	2	1
Current Assets					
Inventories	13	-	-	-	-
Trade and other receivables	14 and 15	5,800	2,264	2,495	14
Cash and bank balances	16	956	198	209	3
Assets of disposal group classified as held for sale	17	-	8	-	-
Total Current Assets		6,756	**2,470**	2,704	**17**
Total Assets		**6,891**	**2,514**	**2,706**	**18**
EQUITY AND LIABILITIES					
Equity attributable to owners of the Company					
Share capital	18	194,890	190,510	194,890	190,510
Translation reserve	19	6	(6)		-
Other reserves	19	(319)	(319)	-	-
Accumulated losses		(191,304)	(190,599)	(192,315)	(191,965)
		3,273	(414)	2,575	(1,455)
Non-controlling interests	20	-	(983)	-	-
Total Equity		**3,273**	**(1,397)**	**2,575**	**(1,455)**
LIABILITIES					
Current Liabilities					
Trade and other payables	21	3,618	3,753	131	1,473
Liabilities directly associated with disposal group classified as held for sale	17	-	158	-	-
Total Current Liabilities		3,618	**3,911**	131	**1,473**
Total Liabilities		3,618	3,911	131	1,473
Total Equity and Liabilities		**6,891**	**2,514**	**2,706**	**18**

C. Condensed interim statements of changes in equity

	Share capital	Translation reserve	Other reserves	Accumulated losses	Total equity attributable to owners of the Company	Non-controlling interests	Total
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
The Group							
2026							
Balance at 1 January 2026	190,510	(6)	(319)	(190,599)	(414)	(983)	(1,397)
Loss for the financial period	-	-	-	(705)	(705)	-	(705)
Other comprehensive income -							
Foreign currency translation	-	12	-	-	12	-	12
Total comprehensive gain/(loss) for the financial period	-	12	-	(705)	(693)	-	(693)
Disposal of a subsidiary	-	-	-	-	-	983	983
Issuance of ordinary shares (non-cash)	1,500	-	-	-	1,500	-	1,500
Issuance of ordinary shares (for cash)	2,880				2,880	-	2,880
Balance as at 30 September 2026	194,890	6	(319)	(191,304)	3,273	-	3,273
2025							
Balance at 1 January 2025	189,710	20	(319)	(190,095)	(684)	(997)	(1,681)
Loss for the financial period	-	-	-	(685)	(685)	(9)	(694)
Other comprehensive income -							
Foreign currency translation	-	2	-	-	2	-	2
Total comprehensive loss for the financial period	-	2	-	(685)	(683)	(9)	(692)
Issuance of ordinary shares (non-cash)	800	-	-	-	800	-	800
Balance at 30 September 2025	190,510	22	(319)	(190,780)	(567)	(1,006)	(1,573)

The Company	Share capital S$'000	Accumulated losses S$'000	Total S$'000
2026			
Balance at 1 January 2026	190,510	(191,965)	(1,455)
Loss for the financial period	-	(350)	(350)
Total comprehensive loss for the financial period	-	(350)	(350)
Issuance of ordinary shares (non-cash)	1,500	-	1,500
Issuance of ordinary shares (for cash)	2,880	-	2,880
Balance as at 30 September 2026	194,890	(192,315)	2,575
2025			
Balance at 1 January 2025	189,710	(191,110)	(1,400)
Loss for the financial period	-	(494)	(494)
Total comprehensive loss for the financial period	-	(494)	(494)
Issuance of ordinary shares (non-cash)	800	-	800
Balance as at 30 September 2025	190,510	(191,604)	(1,094)

D. Condensed interim consolidated statement of cash flows

	Note	The Group 3-months period ended 30/09/2026 (Q3FY2026) Unaudited S$'000	The Group 3-months period ended 30/09/2025 (Q3FY2025) Unaudited S$'000	The Group 9-months period ended 30/09/2026 (9MFY2026) Unaudited S$'000	The Group 9-months period ended 30/09/2025 (9MFY2025) Unaudited S$'000
Cash flows from operating activities					
Loss before income tax, from continuing operation		(1,055)	(279)	(705)	(648)
Loss before income tax, from discontinuing operation		(*)	(16)	(*)	(46)
		(1,055)	(295)	(705)	(694)
Adjustments for:					
Depreciation of property, plant and equipment		7	32	11	94
Gain on termination of right-of-use assets		-	(6)	-	(6)
Unrealised foreign exchange loss		*	*	*	*
Interest income		*	*	*	*
Interest expense		-	2	-	7
Loss on disposal of subsidiary		844	-	844	-
Operating (loss)/profit before working capital changes		(204)	(267)	150	(599)
Changes in working capital					
Trade and other receivables		544	37	(3,536)	(1,692)
Trade and other payables		(1,152)	(341)	1,389	(927)
Cash used in operating activities		(812)	(571)	(1,997)	(3,218)
Interest received		*	*	*	*
Interest paid		-	(2)	-	(7)
Net cash used in operating activities		**(812)**	**(573)**	**(1,997)**	**(3,225)**
Cash flows from investing activities					
Additions of property, plant and equipment		(102)	-	(102)	(4)
Proceeds from disposal of property, plant and equipment		-	-	-	119
Net cash (used in)/generated from investing activities		**(102)**	**-**	**(102)**	**115**

	Note	The Group		The Group	
		3-months period ended 30/09/2026 (Q3FY2026) Unaudited	3-months period ended 30/09/2025 (Q3FY2025) Unaudited	**9-months period ended 30/09/2026 (9MFY2026) Unaudited**	9-months period ended 30/09/2025 (9MFY2025) Unaudited
		S$'000	**S$'000**	**S$'000**	**S$'000**
Cash flows from financing activities					
Proceeds from issuance of ordinary shares, net of share issuance expenses		-	-	-	-
(Repayment to)/Proceeds from loan from an employee		(1,017)	314	(35)	1,749
Repayment of lease liabilities		-	(21)	-	(64)
Proceeds from placement		2,880	-	2,880	-
Net cash generated from/(used in) financing activities		**1,863**	**293**	**2,845**	**1,685**
Net increase/(decrease) in cash and cash equivalents		949	(280)	746	(1,425)
Cash and cash equivalents at beginning of financial period/year		11	320	198	1,467
Effect of currency translation on cash and cash equivalents		(4)	4	12	2
Cash and cash equivalents at end of the financial period/year	16	956	44	956	44

Note:
* denotes values less than S$1,000

E. Notes to the condensed interim consolidated financial statements

1. Corporate information

Metech International Limited (the "**Company**") is incorporated and domiciled in Singapore and whose shares are listed and publicly traded on the Catalist Board of the Singapore Exchange Securities Trading Limited ("**SGX-ST**"). The registered office and principal place of business at 54 Pandan Road, Singapore 609292.

These condensed interim consolidated financial statements as at and for the three months and nine months period ended 30 September 2026 comprise the Company and its subsidiaries (collectively, the "**Group**").

The primary activity of the Company is that of investment holding. The principal activities of the subsidiaries are as follows:

(a) Collection and processing of food waste into animal feed, bio-fuel and other by-products, and the production and sale of agricultural machinery, fermentation and renewable resource equipment (the "**Food Waste Business**"); and

(b) Wholesale distribution of high-quality and affordable nutritional supplements (the "**Health Supplements Business**").

2. Basis of preparation

The condensed interim financial statements for the three months and nine months period ended 30 September 2026 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("**SFRS(I)**") 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last interim financial statements for the period ended 30 June 2026.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore Dollar which is the Company's functional currency.

2.1 New and amended standards adopted by the Group

A number of amendments to standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

Other than as disclosed in the condensed interim consolidated financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2025.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial period are included in the following note:

- Note 11 – Impairment for property, plant and equipment

Management reviews the Group's property, plant and equipment at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the recoverable amount of the property, plant and equipment is estimated to determine the amount of impairment.

During the current financial year, based on external and/or internal sources of information, there are impairment indicators for the Group's property, plant and equipment. The Group's management determined the recoverable amounts of the individual cash-generating units using value-in-use calculations, which involved significant judgements and estimates in estimating the gross and profit margins, expected growth rate and discount rate.

As at the reporting date, the net carrying amount of the Group's property, plant and equipment is disclosed in Note 11.

- Note 13 – Valuation of inventories

The Group measures the inventories in accordance with the accounting policy as disclosed in Note 2. The Group's management measured the inventories at the lower of cost and net realisable value. In ascertaining net realisable value, significant judgements and estimates are involved in estimating the expected selling prices less the estimated costs of completion and the estimated costs to be incurred in marketing, selling and distribution.

The net carrying amount of the Group's inventories is disclosed in Note 13.

2.3 **Going Concern**

The Group incurred a total loss attributable to equity holders of the Company from continuing operations of approximately $705,000 (9MFY2025: $685,000), a total comprehensive loss attributable to equity holders of the Company of approximately $693,000 (9MFY2025: $683,000) and net cash used in operating activities of S$1,997,000 (9MFY2025: S$3,225,000) during 9MFY2026.

Notwithstanding that the Group was in a net current asset position and a net asset position as at 30 September 2026, the Group's cash balance vis-à-vis the Group's net cash used in operating activities and net loss after income tax, may indicate the existence of a material uncertainty which may cast significant doubt on the Group's and the Company's ability to continue as going concerns.

Notwithstanding the above, the directors of the Company believe that the use of the going concern assumption in the preparation and presentation of the financial statements for the nine-month period ended 30 September 2026 is appropriate after taking into consideration the following factors:

i. Management has prepared a cash flow projection for its operations for the next twelve months and is satisfied that the Group will have sufficient cash flow.

ii. The Group has plans to raise capital and obtain additional funds for working capital and the management will continue to evaluate various strategies to obtain alternative sources of finance where necessary to enable the Group to meet its obligations as and when they fall due. In this regard, the Company had (a) completed the placement of 72,000,000 new ordinary shares (the "**Placement Shares**") in the capital of the Company with Mr. Ma Ong Kee ("**Mr. Ma**") and Raffles Capital Limited ("**RCL**") on 30 July 2026 (the "**Placement**"), raising net proceeds of approximately S$2,856,000, and (b) entered into an S$3.0 million interest-free loan with Mr. Cao Shixuan ("**Mr. Cao**") on 6 August 2026 (the "**August 2026 Loan**"). As at 30 September 2026, the Company has not utilised the August 2026 Loan.

iii. The biomass carbon reduction system machines, intended for the pilot trial, have arrived at the factory and have successfully completed testing and commissioning. Concurrently, the Company is actively engaging with corporations across multiple countries and industries to expand into various regional and international markets.

Concurrently, based on information provided by Colorful Paradise Agricultural Cooperation Co., Ltd. ("**CPAC**"), the Company's joint venture partner in Taiwan, the project has received grant support as an approved initiative by the Taiwan authorities, reflecting strong market demand for such machines. To date, orders have been placed for the biomass carbon reduction system machines, underscoring the product's viability. The Company views this as a positive development and will further strengthen its cooperation with CPAC to expand the deployment of the biomass carbon reduction system machines, including discussions on the appropriate business model and commercial arrangements going forward. In view of the grants received from the relevant authorities in Taiwan, the Company is currently in discussions with CPAC in relation to the joint fulfilment of such orders. The Company may also, with CPAC, expand the relevant businesses into the ASEAN region.

In relation to the non-binding memorandum of understanding with MLF Ingredients Sdn. Bhd. ("**MLF**"), the Company is in discussions with MLF on the proposed pricing of its potential high-protein animal nutrition products for the South Korea and United States markets. Concurrently, the Company is exploring collaborations with

neighboring vendors to leverage their established sales networks to expand its global market reach, including in South Korea, the United States, Europe and Asia, while evaluating Malaysia as a potential manufacturing and production base for such products.

The Company possesses the technical know-how to derive high-quality food-grade protein ingredients from food valorization streams and plant-derived sources. The current formulation targets comprise approximately 40% protein derived from food industry by-products and valorization sources, including soy waste, brewer's extract residues and dairy waste streams, with the remaining 60% derived from plant-based ingredients. To validate the protein content of the product, the Company had commissioned an independent third-party laboratory test.

The Company is exploring commercialization opportunities for applications including premium animal feed, baby animal nutrition, senior meal replacement products and infant nutrition formulations, subject to applicable regulatory approvals and market requirements. Management believes the high-quality protein formulations may contribute to improved nutritional outcomes, enhanced digestibility, reduced mortality rates in young animal applications and overall improved health performance.

iv. With respect to the Health Supplements Business, the Company is actively working to grow its health supplement sales by leveraging the health supplements license recently obtained by its supplier to expand marketing efforts and sales outreach across various regions of the People's Republic of China. In anticipation of increased demand, the Company is also working with its supplier to enhance production capacity through factory expansion and investments in additional machinery, while concurrently undertaking the necessary repackaging and production activities.

v. The Group will continue to implement cost-cutting measures.

vi. Mr. Cao has indicated to the Company that he will continue to provide financial support and assistance, where necessary, to enable the Group to meet its obligations as and when they fall due.

In the event that the Group and the Company are unable to continue as going concerns, adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are recorded in the statements of financial position. In addition, the Group and the Company may have to provide for liabilities that might arise, and to reclassify non-current assets as current assets. No such adjustments have been made to these financial statements.

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment and revenue information

The Group has three reportable segments as follows:
(a) The Health Supplements Business;
(b) Manufacturing and distribution of lab-grown diamonds; and
(c) Corporate segment which consists of an investment holding company which does not meet any of its quantitative thresholds for determining a reporting segment.

These operating segments are reported in a manner consistent with internal reporting provided to the former executive committee whose members were responsible for allocating resources and assessing the performance of each segment.

4.1 Reportable segments

	Lab-grown Diamond		Health Supplements Business		Corporate/other		Per consolidated financial statements	
	3 months period ended 30/09/2026 (Q3FY2026)	3 months period ended 30/09/2025 (Q3FY2025)	3 months period ended 30/09/2026 (Q3FY2026)	3 months period ended 30/09/2025 (Q3FY2025)	3 months period ended 30/09/2026 (Q3FY2026)	3 months period ended 30/09/2025 (Q3FY2025)	3 months period ended 30/09/2026 (Q3FY2026)	3 months period ended 30/09/2025 (Q3FY2025)
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
Revenue	-	-	-	-	-	-	-	-
Depreciation and amortisation	(6)	(9)	-	-	(1)	(23)	(7)	(32)
Gain on termination of right-of-use assets	-	-	-	-	-	6	-	6
Loss on disposal of a subsidiary	(844)	-	-	-	-	-	(844)	-
Finance cost	-	-	-	-	-	(2)	-	(2)
Segment loss	(850)	(28)	(22)	(14)	(183)	(253)	(1,055)	(295)
Segment assets	490	171	4,574	1,281	1,827	595	6,891	2,047
Segment liabilities	(21)	(260)	(3,022)	(1,270)	(575)	(2,090)	(3,618)	(3,620)
Capital expenditure								
- Addition to property, plant and equipment	-	-	-	-	-	-	-	-

	Lab-grown Diamond		Health Supplements Business		Corporate / other		Per consolidated financial statements	
	9 months period ended 30/09/2026 (9MFY2026)	9 months period ended 30/09/2025 (9MFY2025)	9 months period ended 30/09/2026 (9MFY2026)	9 months period ended 30/09/2025 (9MFY2025)	9 months period ended 30/09/2026 (9MFY2026)	9 months period ended 30/09/2025 (9MFY2025)	9 months period ended 30/09/2026 (9MFY2026)	9 months period ended 30/09/2025 (9MFY2025)
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
Revenue	-	-	3,210	3,061	-	-	3,210	3,061
Depreciation and amortisation	(6)	(25)	-	-	(5)	(69)	(11)	(94)
Gain on termination of right-of-use assets	-	-	-	-	-	6	-	6
Loss on disposal of a subsidiary	(844)	-	-	-	-	-	(844)	-
Finance cost	-	-	-	-	-	(7)	-	(7)
Segment (loss)/profit	(850)	(92)	576	341	(431)	(943)	(705)	(694)
Segment assets	490	171	4,574	1,281	1,827	595	6,891	2,047
Segment liabilities	(21)	(260)	(3,022)	(1,270)	(575)	(2,090)	(3,618)	(3,620)
Capital expenditure								
- Addition to property, plant and equipment	-	-	-	-	-	-	-	-

4.2 Disaggregation of revenue

	Group		Group	
	3-months period ended 30/09/2026 (Q3FY2026)	3-months period ended 30/09/2025 (Q3FY2025)	9-months period ended 30/09/2026 (9MFY2026)	9-months period ended 30/09/2025 (9MFY2025)
	S$'000	S$'000	S$'000	S$'000
Principal geographical market				
People's Republic of China	-	-	3,210	3,061
Major product or service line and time of recognition				
Performance obligations satisfied at a point in time				
Sale of goods – Health supplements business	-	-	3,210	3,061

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 September 2026 and 31 December 2025:

	Group		Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Financial assets measured at amortised cost				
Trade and other receivables #	5,753	2,257	2,455	10
Cash and cash equivalents	956	198	209	3
Amount due from subsidiaries	-	-	-	-
	6,709	2,455	2,664	13
Financial liabilities measured at amortised cost				
Trade and other payables *	(3,615)	(2,226)	(123)	(762)
Loan from an employee	-	(1,527)	-	(703)
Amount due to subsidiaries	-	-	(8)	(8)
	(3,615)	(3,753)	(131)	(1,473)

Excludes prepayments and GST receivables

* Excludes contract liabilities and GST payables

6. Other income

	Group			
	3-months period ended 30/09/2026 (Q3FY2026)	3-months period ended 30/09/2025 (Q3FY2025)	9-months period ended 30/09/2026 (9MFY2026)	9-months period ended 30/09/2025 (9MFY2025)
	S$'000	S$'000	S$'000	S$'000
Other income:				
Others				
- Government grant	-	-	2	6
- Building management income	155	-	512	-
- Miscellaneous	-	6	7	8
	155	6	521	14

7. Loss before income tax

7.1 Significant items

	Group			
	3-months period ended 30/09/2026 (Q3FY2026)	3-months period ended 30/09/2025 (Q3FY2025)	9-months period ended 30/09/2026 (9MFY2026)	9-months period ended 30/09/2025 (9MFY2025)
	S$'000	S$'000	S$'000	S$'000
Depreciation of property, plant and equipment				
- included in administrative expenses	7	32	11	94
Gain on termination of right-of-use assets	-	(6)	-	(6)
Loss on disposal of a subsidiary	844	-	844	-
Interest expenses on lease liabilities	-	2	-	7
Professional expenses				
- included in administrative expenses	32	81	92	223

8. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Group			
	3-months period ended 30/09/2026 (Q3FY2026)	3-months period ended 30/09/2025 (Q3FY2025)	9-months period ended 30/09/2026 (9MFY2026)	9-months period ended 30/09/2025 (9MFY2025)
	S$'000	S$'000	S$'000	S$'000
Current income tax expenses	-	-	-	-
Current year	-	-	-	-
Reversal of prior year provision	-	-	-	-

As at 30 September 2026, the Group has unutilised tax losses of approximately S$17,205,000 (31 December 2025: S$17,205,000), which are available to offset future taxable profits of those corporate entities within the Group where these losses arise. The utilisation of these unutilised tax losses is subject to the agreement of the relevant tax authorities and compliance with the applicable provisions of the tax regulation in the jurisdictions which the corporate entities of the Group operate. The unutilised tax losses have no expiry dates.

Deferred tax assets arising from these unutilised tax losses and capital allowances of approximately S$2,925,000 (31 December 2025: S$2,925,000) have not been recognised in Q3FY2026.

9. Dividends

No dividend for the period ended 30 September 2026 (30 September 2025: Nil) is recommended.

10. Net asset / (liability) value

	Group		Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
Net asset/(liability) value[(1)] per ordinary share (cents per share)	0.98	(0.21)	0.77	(0.72)
No. of ordinary shares	335,510,200	201,010,200	335,510,200	201,010,200

Note:

(1) Net asset/(liability) value attributable to the owners of the Company

The calculation of net asset/(liability) value per ordinary share of the Group and the Company is based on 335,510,200 shares as at 30 September 2026 (31 December 2025: 201,010,200).

11. **Property, plant and equipment**

	Group				
	Leasehold buildings	**Plant and equipment**	**Motor Vehicle**	**Furniture and fittings and office equipment**	**Total**
	S$'000	**S$'000**	**S$'000**	**S$'000**	**S$'000**
Cost					
Balance at 1 January 2025	268	5,359	-	27	5,654
Additions	-	40	-	4	44
Disposal / Written off	(268)	(5,359)	-	-	(5,627)
Balance at 31 December 2025	-	40	-	31	71
Additions	-	-	102	-	102
Disposal / Written off	-	-	-	-	-
Balance at 30 September 2026	-	40	102	31	173
Accumulated depreciation and impairment					
Balance at 1 January 2025	60	5,092	-	20	5,172
Depreciation for the year	67	26	-	7	100
Disposal / Written off	(127)	(5,118)	-	-	(5,245)
Balance at 31 December 2025	-	-	-	27	27
Depreciation for the year	-	3	6	2	11
Balance at 30 September 2026	-	3	6	29	38
Carrying amount					
Balance at 31 December 2025	-	40	-	4	44
Balance at 30 September 2026	-	37	96	2	135

Note:
Right-of-use assets acquired under leasing arrangement are presented together with the owned assets of the same class.

12. Investment in subsidiaries

	Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Equity investments, at cost	4,020	4,020
Less: Impairment losses	(4,020)	(4,020)
Balance at 30 September 2026 / 31 December 2025	-	-
Impairment losses on equity investments		
Balance at the beginning and end of the period/year	(4,020)	(4,020)

(a) The details of the subsidiaries held by the Group and the Company are as follows:

Name of Company / Country of Incorporation	Principal activities	Percentage of effective equity interest held by the Group 30/09/2026 %	31/12/2025 %
Held by the Company			
Metech Dynamics Pte Ltd. *Singapore*	General wholesale trade (including general importers and exporters) and wholesale trade of a variety of goods without a dominant product	100	100
Asian Green Tech Pte. Ltd. *Singapore*	Engineering design and consultancy services in energy management and clean energy system	100	100
Biovalor Innovations Pte. Ltd. (formerly known as Metech Diamond Pte. Ltd.) *Singapore*	Promoting and selling lab-grown diamonds and gemstones over the internet	100	100
Opulwell Biotechnology Pte. Ltd. (formerly known as Metech Diamond Solutions Pte. Ltd.) *Singapore*	Wholesale of health supplements	100	100
Held by Metech Dynamics Pte. Ltd.			
Zhongxin Minghua (Shanghai) International Trade Co., Ltd. *People's Republic of China*	General wholesale trade	100	100
Held by Asian Green Tech Pte. Ltd.			
Asian Eco Technology Pte. Ltd. *Singapore*	Manufacturing and distribution of lab-grown diamonds	-	80

13. Inventories

	Group	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Raw materials	-	-
Finished goods	-	-
	-	-

Movements in allowance

	Group	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Balance at 1 January 2026 / 2025	39	257
Write off impairment losses	-	(218)
Balance at 30 September 2026 / 31 December 2025	39	39

For the current financial period ended 30 September 2026, finished goods recognised in cost of sales amounted to S$nil (31 December 2025: S$nil) as the cost has been fully impaired in the 18-month financial period ended 31 December 2023 ("**FP2023**").

14. Trade receivables

	Group		Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Trade receivables	4,065	1,421	-	-

Trade receivables are non-interest bearing and generally has credit of 30 to 120 (31 December 2025: 30 to 120) day terms. Loss allowance for trade receivables is measured at an amount equal to lifetime expected credit losses.

The Group's credit risk exposure in relation to trade receivables are set out in the provision matrix as presented below. The Group's provision for loss allowance is based on past due as the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments.

	Lifetime expected loss rate	Gross carrying amounts	Lifetime expected credit losses	Net carrying amounts
	%	S$'000	S$'000	S$'000
Group				
As at 30/09/2026				
> 120 days	100	14	(14)	-
As at 31/12/2025				
Current	100	14	(14)	-

The movements in the allowance account used to record the impairment loss during the financial period / year are as follows:

	Group	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Balance at the beginning and end of the period/year	14	14

15. Other receivables

	Group		Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Other receivables – third parties	822	809	437	437
Advances	235	235	-	-
Deposit	1,303	464	24	10
Amount due from subsidiaries (non-trade)	-	-	10,244	7,864
	2,360	1,508	10,705	8,311
Less: Allowance for impairment losses	(672)	(672)	(8,250)	(8,301)
Financial assets	1,688	836	2,455	10
Prepayments	47	3	40	-
GST receivable	*	4	-	4
	1,735	843	2,495	14

Group level

i) Other receivables – third parties

As disclosed in the Company's announcement dated 13 December 2023, the Company has entered into a settlement agreement with Mr. Deng Yiming ("**Mr. Deng**") where Mr. Deng has agreed to, *inter alia*, pay the Company an amount of S$483,000 with interests accruing at a rate of 5.33% per annum, as awarded by the High Court of the Republic of Singapore. Mr. Deng is to pay in six (6) instalments, commencing from 15 January 2025. The Company has received RMB250,000 (approximately S$46,000) from Mr. Deng as at the date of this announcement. As at the date of this announcement, the Company remains in close contact with Mr. Deng and is following-up and monitoring closely on the receipt of the balance amount. The Company will subsequently make the appropriate announcement(s) as and when there are any material developments in this regard.

Below are the movements of impairment loss during 9MFY2026 and FY2025:

	Group	
	As at 30/09/2026	As at 31/12/2025
	S$'000	S$'000
Balance at the beginning and end of the period/year	437	437

ii) *Advances*

Advance payments of S$235,000 in 9MFY2026 and FY2025 consist of payment to vendors for inventories and to a former non-controlling interest for purchase of lab grown diamonds and business travelling expenses which had been fully impaired in FP2023.

The below are the movements of impairment loss during 9MFY2026 and FY2025:

	Group	
	As at 30/09/2026	As at 31/12/2025
	S$'000	S$'000
Balance at the beginning and end of the period/year	235	235

iii) Deposits

Deposits included rental deposit, deposits placed with the professional parties and in relation to the office at 54 Pandan Road.

Company level

i) Amounts due from subsidiaries (non-trade)

Except for a non-trade balance of S$2,798,000 (FY2025: S$2,798,000) due from subsidiaries as at 30 September 2026, which is non-trade in nature, unsecured, interest bearing at 6% per annum, the remaining non-trade balance of S$7,446,000 (FY2025: S$5,066,000) due from subsidiaries are unsecured, interest-free and repayable on demand.

The movements in the allowance account used to record the impairment loss during the financial period / year are as follows:

	Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Balance at 1 January 2026 / 2025	7,864	8,238
Reversal of impairment loss recognised in profit or loss	(51)	(374)
Balance at 30 September 2026 / 31 December 2025	7,813	7,864

16. Cash and cash equivalents

	Group		Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Cash and bank balances	956	198	209	3

Bank balances are interest-bearing. Interest earned during the current and previous financial period/year are considered insignificant.

17. Discontinued operations and disposal group classified as held for sale

The Company had, on 4 October 2025, announced the proposed disposal of its entire shareholdings of 80% of the issued and paid-up share capital of AET to Wuhan Xilu Trading Co., Ltd. (the "**Proposed Disposal**").

The Company had, on 30 April 2026, obtained Shareholders' approval for the Proposed Disposal, and the Proposed Disposal was completed on 26 August 2026. Accordingly, AET has ceased to be a subsidiary of the Company on the same date.

18. Share capital

	As at 30/09/2026		As at 31/12/2025	
	No. of shares	Amount S$'000	No. of shares	Amount S$'000
Issued and fully paid:				
Balance at beginning of interim period/year	263,510,200	192,010	201,010,200	190,510
Issuance of ordinary shares	72,000,000	2,880	-	-
Balance at the end of the period/year	335,510,200	194,890	201,010,200	190,510

The Company had, on 30 July 2026, completed the Placement of 72,000,000 Placement Shares to Mr. Ma and RCL.

Save as disclosed above, there were no other changes in the Company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities or for any other purpose since the end of the previous period reported on, being 30 June 2026.

The total number of issued shares excluding treasury shares as at 30 September 2026 and 31 December 2025 were 335,510,200 shares and 201,010,200 shares, respectively.

The Company had no outstanding convertibles, treasury shares and subsidiary holdings as at 30 September 2026 and 30 September 2025, respectively.

There were no sales, transfers, cancellation and/or use of treasury shares or subsidiary holdings during the three-month period ended and as at 30 September 2026.

19. Other reserves

Other reserves

	Group	
	As at 30/09/2026	As at 31/12/2025
	S$'000	S$'000
Balance at the beginning and end of the period/year	(319)	(319)

Translation reserve

	Group	
	As at 30/09/2026	As at 31/12/2025
	S$'000	S$'000
Balance at beginning of interim period	(6)	20
Exchange differences on currency translation differences	12	(26)
Balance at the end of the period/year	6	(6)
Other reserves at the end of the period/year	(313)	(325)

20. Non-controlling interest

The non-controlling interest relates to the remaining 20% shares in AET not held by the Company.

21. Trade and other payables

	Group		Company	
	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/09/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Trade payables	1,419	1,402	-	-
Sundry creditors	1,938	460	327	433
GST payable	3	-	3	-
Accruals for:				
- professional fees	91	108	83	94
- staff costs	77	79	57	58
- directors' fee	90	177	90	177
Amount due to subsidiaries (non-trade)	-	-	8	8
Loan/Advances from an employee *	-	1,527	(437)	703
	3,618	3,753	131	1,473

The non-trade balances due to subsidiaries are unsecured, interest-free and repayable on demand.

* The loan/advances from an employee are unsecured, interest-free, and the amounts are repayable within one year on demand.

As at 30 September 2026, there are no outstanding amounts under the loan payable to the employee.

Save as disclosed in this announcement, the Group does not have any other borrowings and/or debt securities as at 30 September 2026 and 31 December 2025.

22. Subsequent events

The Company had, on 7 October 2026, entered into a non-binding memorandum of understanding with Zhejiang Kesheng Feed Co., Ltd ("**ZJKS**"), a company based in Zhejiang province, the People's Republic of China, for the joint research, development and commercialisation of a black soldier fly bioconversion system (the "**Proposed ZJKS Collaboration**"). Please refer to the announcement dated 7 October 2026 for further information in relation to the Proposed ZJKS Collaboration.

OTHER INFORMATION REQUIRED PURSUANT TO APPENDIX 7C OF THE CATALIST RULES

1. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The condensed interim consolidated statement of profit or loss and other comprehensive income of Metech International Limited (the "**Company**", and its subsidiaries, collectively, the "**Group**") as at 30 September 2026 and the related condensed interim consolidated statements of financial position, condensed interim consolidated statement of changes in equity, condensed profit or loss and other comprehensive income and consolidated statement of cash flows for the three month and nine month period ended and certain explanatory notes have not been audited or reviewed.

2. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).

Not applicable.

2A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

(a) Updates on the efforts taken to resolve each outstanding audit issue.

(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

3. A review of the performance of the group, to the extent necessary for a reasonable understanding of the Group's business. It must include a discussion of the following:

(a) any significant factors that affected the turnover, costs, and earnings of the Group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and

Review for the performance of the Group for Q3FY2026 and 9MFY2026

(i) Revenue

The Group did not generate any revenue in Q3FY2026 and Q3FY2025. In Q3FY2026, the absence of revenue was mainly attributable to the ongoing repackaging of the health supplement products and discussions with our suppliers regarding the potential launch of new products in the market.

In 9MFY2026, the Group generated revenue of approximately S$3.21 million, representing a slight increase of approximately S$0.15 million, as compared to revenue of approximately S$3.06 million in 9MFY2025.

(ii) Cost of sales

In Q3FY2026 and Q3FY2025, the Group recorded cost of sales of approximately S$nil as no revenue was generated during the periods.

In 9MFY2026, the Group's cost of sales decreased by approximately S$0.11 million, from approximately S$2.72 million in 9MFY2025 to approximately S$2.61 million in 9MFY2026. The decrease in cost of sales was mainly due to the Company's negotiation for lower purchase prices with its suppliers for the Health Supplements Business, leading to a higher gross profit margin achieved.

(iii) Gross profit/(loss)

As a result of the above, the Group generated a gross profit of approximately S$nil in both Q3FY2026 and Q3FY2025.

For 9MFY2026, the Group recorded a gross profit of approximately S$0.61 million, as compared to a gross profit of approximately S$0.34 million in 9MFY2025.

Accordingly, this represented an increase in gross profit margin of approximately 7.81%, from approximately 11.04% in 9MFY2025 to approximately 18.85% in 9MFY2026.

(iv) Other income

In Q3FY2026, the Group recorded an increase in other income of approximately S$0.15 million, from approximately S$6,000 in Q3FY2025 to approximately S$0.16 million in Q3FY2026. The increase was mainly due to the building management income generated from the management of the building at 54 Pandan Road.

In 9MFY2026, the Group recorded an increase in other income of approximately S$0.51 million, from approximately S$14,000 in 9MFY2025 to approximately S$0.52 million in 9MFY2026. The increase was mainly due to the building management income generated from the management of the building at 54 Pandan Road.

(v) Administrative expenses

In Q3FY2026, administrative expenses increased by approximately S$0.93 million, from approximately S$0.28 million in Q3FY2025 to approximately S$1.21 million in Q3FY2026. This increase was mainly attributed to the one-off non-cash loss arising from the completion of the disposal of AET during the financial period.

In 9MFY2026, administrative expenses increased by approximately S$0.84 million from approximately S$0.99 million in Q3FY2025 to approximately S$1.83 million in 9MFY2026. This increase was mainly attributed to the one-off non-cash loss arising from the completion of the disposal of AET during the financial period.

(vi) Finance costs

Finance costs of approximately S$2,000 and S$7,000 were incurred in Q3FY2025 and 9MFY2025, respectively. No such finance costs were incurred in Q3FY2026 and 9MFY2026.

Finance costs in Q3FY2025 and 9MFY2025 were attributed to the amortisation of interest expense from lease liabilities. No finance costs were incurred in Q3FY2026 and 9MFY2026 following the termination of the relevant lease in FY2025.

(vii) Loss from continuing operations

As a result of the above, the Group's loss before and after income tax increased by approximately S$0.76 million in Q3FY2026, from a loss before and after income tax of approximately S$0.30 million in Q3FY2025, to approximately S$1.06 million in Q3FY2026, mainly due to the one-off non-cash loss arising from the completion of the disposal of AET during the financial period.

The Group's loss before and after income tax was approximately S$0.71 million and S$0.69 million in 9MFY2026 and 9MFY2025, respectively, which was mainly attributed to the one-off non-cash loss arising from the completion of the disposal of AET during the financial period.

Loss from discontinued operations amounted to less than S$1,000 in Q3FY2026, as compared to approximately S$10,000 in Q3FY2025. Similarly, loss from discontinued operations amounted to less than S$1,000 in 9MFY2026, as compared to approximately S$27,000 in 9MFY2025.

(viii) Foreign currency translation difference

Foreign currency translation difference was a loss of approximately S$4,000 in 3QFY2026, as compared to a gain of approximately S$4,000 in 3QFY2025. This was mainly due to the fluctuation of foreign currency exchange rates between the US Dollar ("**USD**") and Singapore Dollar ("**SGD**"), and between SGD and Chinese Yuan ("**RMB**") during the financial period.

Foreign currency translation difference was a gain of approximately S$12,000 in 9MFY2026, as compared to a gain of S$2,000 in 9MFY2025. This was mainly due to the fluctuation of foreign currency exchange rates between the USD and SGD, and between SGD and RMB during the financial period.

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the Group during the current financial period reported on

Condensed interim statements of financial position

Assets

(i) Property, plant and equipment increased by approximately S$91,000, from approximately S$44,000 as at 31 December 2025 to approximately S$135,000 as at 30 September 2026. The increase was due to the acquisition of motor vehicle, which was partially offset by depreciation charges recorded in 9MFY2026.

(ii) Trade and other receivables had increased by approximately S$3.54 million, from approximately S$2.26 million as at 31 December 2025 to approximately S$5.80 million as at 30 September 2026. The increase was mainly attributed to recognition of trade receivables arising from the sale of health supplements, and deposits placed in relation to the office premises at 54 Pandan Road.

(iii) Cash and bank balances have increased by approximately S$758,000 from approximately S$198,000 as at 31 December 2025 to approximately S$956,000 as at 30 September 2026 and the movements as reflected in the statement of cash flows are explained below.

(iv) Disposal group assets classified as held for sale of approximately S$8,000 as at 30 June 2026 are mainly related to the assets of AET. Please refer to Note 17 for further information of the Proposed Disposal.

Liabilities

(v) Trade and other payables had decreased by approximately S$0.13 million from approximately S$3.75 million as at 31 December 2025 to approximately S$3.62 million as at 30 September 2026. The decrease was due to the recognition of trade creditors arising from the Health Supplements Business and increase in other payables, which was partially offset by the repayment of advances/loan to the employee.

(vi) Liabilities directly associated with disposal group classified as held for sale of approximately S$0.15 million are mainly related to the liabilities of AET. Please refer to Note 17 for further details of the Proposed Disposal.

Working capital

The Group had recorded an improvement in its working capital position by approximately S$4.58 million, reversing from a negative working capital position of S$1.44 million as at 31 December 2025 to a positive working capital position of S$3.14 million as at 30 September 2026. The improvement was mainly attributable to (a) an increase in trade and other receivables of approximately S$3.54 million, (b) the debt capitalisation exercise for an aggregate amount of S$1.50 million which was completed on 2 June 2026, (c) the completion of the Placement on 30 July 2026, (d) the completion of the Proposed Disposal and (e) decrease in trade and other payables of approximately S$0.14 million.

Condensed interim consolidated statement of cash flows

Q3FY2026

The Group recorded an increase in net cash used in operating activities of approximately S$0.24 million, from approximately S$0.57 million in Q3FY2025, to approximately S$0.81 million in Q3FY2026. This was mainly due to an increase in trade and other payables, which was partially offset by the one-off non-cash loss arising from the completion of AET and a decrease in trade and other receivables.

The Group recorded S$0.10 million in investing activities in Q3FY2026, mainly due to the acquisition of a motor vehicle. No cash flows from investing activities were recorded in Q3FY2025.

Net cash of approximately S$1.86 million was generated from financing activities of the Group in Q3FY2026, due to the completion of the Placement, which was partially offset by the repayment of loan/advances to an employee.

As a result of the above, the Group's cash and cash equivalents as at 30 September 2026 increased by approximately S$0.95 million, from approximately S$11,000 as at 1 July 2026, to approximately S$0.96 million, after taking into consideration the loss on currency translation on cash and cash equivalents of approximately S$4,000.

9MFY2026

The Group recorded a decrease in net cash used in operating activities of approximately S$1.23 million, from approximately S$3.23 million in Q3FY2025, to approximately S$2.0 million in Q3FY2026. This was mainly due to (a) an increase in trade and other payables and (b) one-off non-cash loss arising from the disposal of AET, which was partially offset by an increase in trade and other receivables.

The Group recorded net cash used in investing activities of approximately S$0.10 million in 9MFY2026, mainly due to the acquisition of motor vehicle, as compared to net cash generated from investing activities of approximately S$0.12 million in 9MFY2025.

Net cash generated from financing activities of the Group increased by approximately S$1.26 million, from approximately S$1.69 million in 9MFY2025 to approximately S$2.85 million in 9MFY2026. The increase was mainly due to the completion of the Placement.

As a result of the above, the Group's cash and cash equivalents as at 30 September 2026 increased by approximately S$0.75 million, from approximately S$0.20 million as at 1 January 2026 to approximately of S$0.96 million as at 30 September 2026, after taking into consideration the gain due to currency translation on cash and cash equivalents of approximately S$12,000.

4. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable as no specific forecast or a prospect statement was previously issued.

5. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next operating period and the next 12 months

The Health Supplements Business

The Company had diversified into the wholesale distribution of health supplements following the approval from shareholders at the extraordinary general meeting held on 30 December 2025. The Company is currently in the process of applying for (i) a sales license and (ii) a health supplements license in the PRC. Securing these licenses would enable the Company to directly commence sales in the PRC, thereby expanding its sales channel within the PRC market and potentially generating revenue from this new market.

The health products market is increasingly shifting towards personalised wellness, as consumers seek effective, science-backed solutions tailored to their individual needs. The Company notes these emerging trends, including but not limited to, the following:

(a) Personalised Wellness: Consumers are seeking tailored experiences for their respective individual needs;

(b) Gut Health: Growing interest in gut-related products, such as probiotics, prebiotics, and gut-friendly foods.

(c) Mental Wellness: Stress management, mindfulness, and mental health products.

(d) Functional Foods and Beverages: Products with added health benefits like energy boosters, digestive aids, and brain food are in demand.

(e) Digital Health: Virtual health services and digital wellness solutions such as health tracking applications and wearables.

(f) Consumer Behaviour:

- Based on a survey conducted by McKinsey & Company (2026), millennials and Gen Zs are prioritising wellness as a daily lifestyle, driving demand for goods and services in six wellness subcategories (i.e., functional nutrition, healthy aging, beauty, in-person wellness services, weight management, and mental health).

- Growing preference from consumers to lean towards holistic wellness solutions, blurring the lines between nutrition, beauty, and mental well-being.

As the health supplements industry evolves, the Company is positioning itself to capitalise on the trends outlined above and aims to do so through collaboration and by leveraging Burpple's technology through the Proposed Burpple Collaboration (as defined herein).

The Food Waste Business

The biomass carbon reduction system machines are expected to enter the initial commercial testing phase in Singapore in the near term, and the Company expects to commence the food waste management in the latter part of FY2026. The Company is currently negotiating with several potential third-party operators for the Food Waste Business, as well as with CPAC in relation to the proposed joint venture company.

In addition, in relation to the memorandum of understanding ("**MOU**") with MLF, and as disclosed in the Company's monthly update announcement for the month of July on 31 July 2026, the Company had conducted a sample feed analysis in July, and based on the sample feed analysis report, the analysis had shown a significantly high protein content, reflecting potential economic value. Accordingly, the Company hopes to enter into initial commercial testing with MLF, followed by commercial production upon the arrival of the biomass carbon reduction system machines in Singapore (the "**Proposed MLF Collaboration**").

The Company had also entered into a non-binding MOU with ZJKS for the Proposed ZJKS Collaboration. Please refer to the announcement dated 7 October 2026 for further information in relation to the Proposed ZJKS Collaboration.

6. If a decision regarding dividend has been made:

(a) Whether an interim (final) ordinary dividend has been declared (recommended); and
No.

(b) (i) Amount per share
Not applicable.

(ii) Previous corresponding period
No dividend has been declared or recommended for the previous corresponding period.

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).
Not applicable.

(d) The date the dividend is payable
Not applicable.

(e) The date on which Registrable Transfers received by the Company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.
Not applicable.

7. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend has been declared or is recommended as the Group is currently focused on its business expansion and restructuring, and the Group currently does not have accumulated profits available for the declaration of dividend.

8. Interested person transactions ("IPTs")

There was no interested person transaction amounting to S$100,000 and above during the financial period under review. The Group has not obtained a general mandate from its shareholders for IPTs.

9. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules

The Company hereby confirms that it has procured signed undertakings from all its directors and executive officers in the format set out in Appendix 7H of the Catalist Rules in accordance with Rule 720(1) of the Catalist Rules.

10. Negative Confirmation Pursuant to Rule 705(5) of the Catalist Rules

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the condensed interim financial statements for the three months and nine months period ended 30 September 2026 to be false or misleading in any material aspect.

11. Use of proceeds from the Placement

The Company had, on 30 July 2026, completed the Placement of 72,000,000 Placement Shares. The net proceeds raised was S$2,856,000 (the "**Net Proceeds**").

The Company had on 15 July 2026 and 22 September 2026 reallocated the Net Proceeds to include the repayment of loans amounting to an aggregate amount of S$1,041,000 (the "**Reallocation**"). The changes in and the details on the use of the Net Proceeds as at the date of this announcement are as follows:

	Allocation (S$'000)	**Allocation after the Reallocation (S$'000)**	**Amount utilised (S$'000)**	**Balance (S$'000)**
General working capital purposes	2,856	1,815	(911)	904
Repayment of loans	-	1,041	(1,041)	-
Total	2,856	2,856	1,952	904

General working capital purposes refer to (a) professional fees of S$283,000, (b) employee salaries and benefits expenses of S$202,000, (c) Directors' fees of S$116,000, (d) office related expenses of S$76,000 and (e) administrative and miscellaneous expenses of S$234,000.

12. Disclosure of acquisitions (including incorporations) and realisations of shares since the end of the previous reporting period pursuant to Rule 706A of the Catalist Rules

On 4 October 2025, the Company announced that it had, on 2 October 2025, through its wholly-owned subsidiary, Asian Green Tech Pte. Ltd. (the "**Vendor**"), entered into a conditional sale and purchase agreement (the "**S&P**") with Wuhan Xilu Trading Co., Ltd. (the "**Purchaser**") for the proposed disposal of 4,106,120 ordinary shares in AET (the "**Sale Shares**"), representing 80.0% of the total issued and paid-up share capital of AET, for a total cash consideration of S$1.00.

Based on the audited financial statements of AET for FY2024, the net liability value and net tangible liability value ("**NTL**") of AET was approximately S$4.97 million as at 31 December 2024, of which approximately S$3.97 million was attributable to the Sale Shares.

Based on the management accounts of AET for the 6-month financial period ended 30 June 2025, the net liability value and the NTL of AET was approximately S$5.0 million as at 30 June 2025, of which approximately S$4.0 million was attributable to the Sale Shares.

Pursuant to the terms and conditions of the S&P, from the date of completion of the Proposed Disposal, the Purchaser shall, in its capacity as the new owner of the Sale Shares, assume and undertake and agree to pay, perform and discharge any and all liabilities, obligations or commitments of AET of any nature whatsoever, whether asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or immature, or otherwise. These amounts include (a) other payables to third parties as well as (b) the accruals, amounting to an aggregate amount of approximately S$0.27 million (the "**Payables**") based on the management accounts of AET as at 30 June 2025.

In consideration of the above, the Vendor agreed to waive off all loan and amounts due to related corporations (being entities within the Group) of approximately S$4.78 million as at 30 June 2025 (the "**Waiver**"). For the avoidance of doubt, allowances for impairment losses for the Waiver amounts had already been provided for by the Company as at 30 June 2025.

The cash consideration of S$1.00 was arrived at after arms' length negotiations between the Vendor and the Purchaser, on a 'willing-buyer and willing-seller' basis, and taking into account, *inter alia,* the negative book value of AET, the Waiver, the Payables as well as the operating status of AET.

The Proposed Disposal was completed on 26 August 2026, and accordingly, upon completion, AET has ceased to be a subsidiary of the Company.

On behalf of the Board of Directors

Pang Wei Hao
Chief Executive Officer and Executive Director

Er Kwong Wah
Independent Director

14 November 2026